A Kidney Drug Doctors Used Sparingly May Help Millions More, Three Landmark Trials Find

A drug that doctors have reached for only cautiously may turn out to help millions more patients than its current label allows, according to a trio of major studies that landed with rare force in the medical world. Finerenone, a pill already used to protect the kidneys of some people with diabetes, was shown to slow kidney decline and reduce the risk of heart failure, cardiovascular death and dying from any cause across a much broader population.

The findings were presented at the European Renal Association Congress in Glasgow and published simultaneously in three of the most prestigious journals in medicine — The Lancet, The New England Journal of Medicine and JAMA. Having a single line of research appear at once in all three is a rarity that signals just how significant specialists consider the results, and how quickly they could reshape treatment guidelines for chronic kidney disease.

Across the studies, finerenone cut the combined risk of kidney failure, progression of chronic kidney disease, heart failure or cardiovascular death by roughly 23 percent. Crucially, the benefit was not confined to patients with diabetes, the group for which the drug is mainly prescribed today. Researchers saw improvements in people with non-diabetic kidney disease and glomerular conditions — patients who often have few good options and who have largely been left out of the drug's approved uses.

Chronic kidney disease is a vast and underappreciated public-health problem, affecting hundreds of millions of people worldwide and frequently progressing silently toward dialysis or transplant while quietly raising the risk of heart attacks and strokes. A medicine that can slow that decline and protect the heart at the same time, in a wider range of patients, addresses two of the deadliest threats those patients face with a single daily tablet.

Finerenone, marketed as Kerendia, belongs to a class of drugs known as non-steroidal mineralocorticoid receptor antagonists, which blunt the effects of hormones that drive inflammation and scarring in the kidneys and heart. The researchers cautioned that expanding its use will require regulators to weigh the new evidence and update prescribing guidance, and that doctors must still monitor patients for side effects such as elevated potassium. But the scale and consistency of the benefit, demonstrated across multiple trials and patient groups, makes a strong case that a drug now used sparingly deserves a far larger role in protecting kidneys and hearts. Patient advocates said the prospect of extending a proven, once-daily therapy to people with non-diabetic kidney disease — long an afterthought in drug development — could meaningfully change the outlook for a population that has watched treatment advances pass it by for decades.